20.98
0.39 (1.89%)
| Previous Close | 20.59 |
| Open | 20.28 |
| Volume | 24,451 |
| Avg. Volume (3M) | 284,817 |
| Market Cap | 673,986,688 |
| Price / Sales | 110.01 |
| Price / Book | 1.88 |
| 52 Weeks Range | |
| Earnings Date | 7 May 2025 - 12 May 2025 |
| Operating Margin (TTM) | -2,406.94% |
| Diluted EPS (TTM) | -2.55 |
| Quarterly Revenue Growth (YOY) | 190.20% |
| Total Debt/Equity (MRQ) | 0.42% |
| Current Ratio (MRQ) | 15.22 |
| Operating Cash Flow (TTM) | -78.18 M |
| Levered Free Cash Flow (TTM) | -43.48 M |
| Return on Assets (TTM) | -23.01% |
| Return on Equity (TTM) | -32.60% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Dianthus Therapeutics, Inc. | Bearish | Bullish |
AIStockmoo Score
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | 4.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | 2.00 |
|
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 8.07% |
| % Held by Institutions | 110.61% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Avidity Partners Management Lp | 31 Dec 2024 | 2,873,000 |
| Fairmount Funds Management Llc | 31 Dec 2024 | 2,700,691 |
| Bain Capital Life Sciences Investors, Llc | 31 Dec 2024 | 2,689,707 |
| Octagon Capital Advisors Lp | 31 Dec 2024 | 2,110,167 |
| Ra Capital Management, L.P. | 31 Dec 2024 | 1,866,400 |
| Vr Adviser, Llc | 31 Dec 2024 | 1,744,373 |
| Tcg Crossover Management, Llc | 31 Dec 2024 | 1,501,624 |
| Braidwell Lp | 31 Dec 2024 | 1,206,589 |
| Alliancebernstein L.P. | 31 Dec 2024 | 1,159,776 |
| Janus Henderson Group Plc | 31 Dec 2024 | 1,085,648 |
| Vestal Point Capital, Lp | 31 Dec 2024 | 1,075,000 |
| 5Am Venture Management, Llc | 31 Dec 2024 | 1,027,711 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 84.00 (Guggenheim, 300.38%) | Buy |
| Median | 40.00 (90.66%) | |
| Low | 36.00 (Wedbush, 71.59%) | Buy |
| Average | 53.33 (154.19%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 21.90 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Guggenheim | 12 Mar 2025 | 84.00 (300.38%) | Buy | 21.90 |
| HC Wainwright & Co. | 12 Mar 2025 | 40.00 (90.66%) | Buy | 21.90 |
| Wedbush | 12 Mar 2025 | 36.00 (71.59%) | Buy | 21.90 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 11 Mar 2025 | Announcement | Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q4 and FY 2024 Financial Results |
| 05 Mar 2025 | Announcement | Dianthus Therapeutics Strengthens Strategic Commercial Leadership With Appointment of John C. King as Chief Commercial Officer and Welcomes Sujay Kango, A Seasoned Commercial Leader, to Board of Directors |
| 26 Feb 2025 | Announcement | Dianthus Therapeutics to Participate in Two Upcoming Investor Conferences |
| 30 Jan 2025 | Announcement | Dianthus Therapeutics to Webcast Presentations at Two Investor Conferences |
| 08 Jan 2025 | Announcement | Dianthus Therapeutics to Webcast Presentation at the 43rd Annual J.P. Morgan Healthcare Conference |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |